determination and sound planning this process could be completed in three to five years; without it we shall have made little progress in the next decade.
Awareness of this problem prompted the European Organization for Research into the Treatment of Cancer (EORTC) to form a Urological Group in 1975 which is now actively investigating some of the problems presented by patients with bladder and prostatic cancer. At present, membership of this group in the United Kingdom is largely confined to urological surgeons in Yorkshire cooperating in the Yorkshire Urological Cancer Research Group (YUCRG) . In the initial study a combination of adriamycin and 5-fluorouracil in patients with advanced bladder cancer suggested a 35-40% remission rate (Cross et al. 1976 ). This regime was then used as an adjuvant to radical radiotherapy in patients with category T3 bladder cancer to determine the potential toxicity of this combination. The results in 18 patients (Glashan et al. 1977) showed no evidence of toxicity after the first 4 cycles of treatment following radiotherapy, but increasing toxicity and patient resistance between 4 and 11 cycles. In two patients late cardiac failure developed. This group of patients has now completed its one, two and three-year follow up, with survival figures of 82%, 55% and 39% respectively, which compare favourably with the London Hospital's trial reported by Wallace & Bloom (1976) . Although such a small group is neither a randomized study nor statistically evaluable, it does suggest that the use of adjuvant chemotherapy in this difficult clinical situation is unlikely to be prejudicial and may have longterm benefit. We have now commenced a randomized trial of chemotherapy using 5fluorouracil and adriamycin or no additional treatment following radical radiotherapy for patients with category T3 NX MO bladder cancer, and hope to be able to give a preliminary evaluation of this study within the next two years.
